| Particulars (Rupees in Crores.) | Sept-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 |
|---|---|---|---|---|---|
Gross Sales | 642.9 | 857.7 | 910.6 | 450.8 | 490.7 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 642.9 | 857.7 | 910.6 | 450.8 | 490.7 |
Other Operating Income | 7.6 | 3.2 | 2.5 | 11.1 | 2.2 |
Other Income | 1.4 | 3 | 0.8 | 3.8 | 9.9 |
Total Income | 651.9 | 863.9 | 913.9 | 465.7 | 502.8 |
Total Expenditure | 661.7 | 705.3 | 723.1 | 447.1 | 473.3 |
PBIDT | -9.8 | 158.6 | 190.8 | 18.6 | 29.5 |
Interest | 15.7 | 2.5 | 4.2 | 3.3 | 0.9 |
PBDT | -25.5 | 156.1 | 186.6 | 15.3 | 28.6 |
Depreciation | 25.1 | 10.8 | 13.2 | 5.2 | 4.9 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 8.9 | 0.8 | -0.1 | 0.2 | 0 |
Deferred Tax | -6.7 | 16.6 | 1.6 | 3.5 | 2.8 |
Reported Profit After Tax | -52.8 | 127.9 | 171.9 | 6.4 | 20.9 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | -52.8 | 127.9 | 171.9 | 6.4 | 20.9 |
Extra-ordinary Items | -28.18 | 0 | 0 | 0 | 5.2 |
Adjusted Profit After Extra-ordinary item | -24.62 | 127.9 | 171.9 | 6.4 | 15.7 |
EPS (Unit Curr.) | -1.66 | 20.1 | 27.01 | 1.01 | 3.28 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 63.6 | 63.6 | 63.6 | 63.6 | 63.6 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | -1.52 | 18.49 | 20.95 | 4.12 | 6.01 |
PBDTM(%) | -3.96 | 18.19 | 20.49 | 3.39 | 5.82 |
PATM(%) | -8.21 | 14.91 | 18.87 | 1.41 | 4.25 |
For FY25, it reported an adjusted operating profit of £21 million, with margins of 15.6%, ahead of Zydus Wellness’ own margins of about 14%.
With this, the UK company is now a wholly owned subsidiary of Alidac and becomes a step-down subsidiary of Zydus Wellness.
PAT margin came sharply at 1.4% against 0.1% in the same quarter last year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
